Press release
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report 2024, Size, Share And Trends
The Business Research Company recently released a comprehensive report on the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.According to The Business Research Company's, The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has grown strongly in recent years. It will grow from $5.24 billion in 2023 to $5.69 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.67 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report
Market Drivers and Trends:
The increasing number of people with diabetes is expected to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market going forward. Diabetes refers to a chronic metabolic disorder characterized by high blood sugar levels (hyperglycemia) over a prolonged period. This condition results from the body's inability to produce enough insulin or effectively use the insulin it produces. EPI therapy, which involves pancreatic enzyme replacement therapy (PERT), can help improve nutrient absorption in people with diabetes and EPI. It can also help improve glycemic control in people with diabetes. For instance, in November 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of over 230 national diabetes associations, approximately 537 million adults (20-79 years old) were living with diabetes in 2021, whereas the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increasing number of people with diabetes is driving the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
Major companies operating in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are focused on innovating new studies and solutions, such as PACT-CP to sustain their position in the market. For instance, in June 2021, Aimmune Therapeutic, a US-based biopharmaceutical company, launched PACT-CP, a patient-centric chronic pancreatitis registry study, to better understand the unmet needs and therapeutic burden on patients with EPI due to chronic pancreatitis (CP). It is the first real-world registry study for patients with chronic pancreatitis. The study, which will follow about 400 patients at 20 gastroenterology facilities across the United States, was created with the help of patients and expert consultants. The PACT-CP Registry study is a prospective, non-interventional research study for patients receiving gastroenterology treatment diagnosed with EPI due to chronic pancreatitis.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
Major Key Players of the Market:
Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2024 Key Insights:
• The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market is expected to grow to$7.67 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%.
• Rising Diabetes Prevalence Fuels Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market
• Innovative Studies And Solutions Drive Advancements In The Epi Therapeutics And Diagnostics Market
• North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2023.
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=12992&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report 2024, Size, Share And Trends here
News-ID: 3674726 • Views: …
More Releases from The Business research company

Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…

Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…

Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…

Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for EPI
Consumer Electronics Adoption Fuels The Silicon Epi Wafer Market: Core Growth En …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Will the Silicon EPI Wafer Industry Market Size Be by 2025?
Over recent years, the market size for silicon EPI wafers has seen considerable growth. Predictions indicate an increase from $1.8 billion in 2024 to $1.92 billion in 2025, representing a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this historical…
Evolving Market Trends In The Silicon EPI Wafer Industry: Next-Generation Silico …
The Silicon EPI Wafer Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Silicon EPI Wafer Market Size During the Forecast Period?
In recent times, the silicon EPI wafer market has witnessed substantial growth. The market size, which stood at $1.8 billion in…
Leading Growth Driver in the Silicon EPI Wafer Market in 2025: Consumer Electron …
What industry-specific factors are fueling the growth of the silicon epi wafer market?
The silicon EPI wafer market is expected to experience significant growth due to the increased use of consumer electronics products. Consumer electronics (CE) refers to electronic devices specifically designed for everyday use by consumers for non-commercial or professional purposes. Silicon wafers, which are semiconductors, are used in the manufacture of microchips and chips for these electronic devices. For…
EPI Invests $1 Million USD in the EPI Data Center Futurist Scholarship Program
Singapore (15 June 2023) - EPI, the global leader in data center training, audit & certification, is proud to announce the launch of the EPI Data Center Futurist Scholarship program, accompanied by a significant investment of one (1) million US-Dollar. This transformative initiative aims to provide aspiring professionals with the resources and support they need to acquire the specialized knowledge and skills necessary for success in the dynamic data…
Epi Wafer Market to Surpass Valuation of US$ 5.8 Bn by 2030 with Rising Demand f …
The global Epi Wafer market is estimated to attain a valuation of US$ 5.8 billion by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6% during the forecast period, 2021-2031.
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of…
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease.
Download the sample report at: https://www.pharmaproff.com/request-sample/1024
Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI…